Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.


vial of Immunocidin Equine product

Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians

An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).

horse's face after 4 Immunocidin treatments

Equine Sarcoid Tumor Product Now Available to U.S. Veterinarians

NovaVive now offers an equine-specific version of its Immunocidin® product for equine sarcoids in response to demand by U.S. veterinarians. Immunocidin® Equine is packaged in 5mL vials for the convenience of practitioners.

mare with foal in field

Settle®: A Regulator-Approved Antibiotic Alternative for Treating Equine Endometritis

NovaVive offers an alternative to antibiotics for the treatment of equine endometritis: Settle®. This product is fully approved by regulators in the U.S. and Australia for endometritis caused by Streptococcus zooepidemicus.

close-up of horse's face

U.S. and Canadian Regulator-Approved Immunotherapeutic Available for Equine Sarcoid Tumors

NovaVive's cancer immunotherapy, Immunocidin(R), received USDA and CFIA approval for the treatment of equine sarcoid tumors in February, 2016. The Company believes that this is North America's first approved sarcoid therapy.

Sign up to stay up-to-date with NovaVive news.